From Surf Wiki (app.surf) — the open knowledge base
Simnotrelvir/ritonavir
Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, a CYP3A inhibitor.
| Column 1 |
|---|
| Chemical structures of simnotrelvir (top) and ritonavir (bottom) |
| SARS-CoV-2 3CLpro inhibitor |
| Protease inhibitor |
| 先诺欣 (Xiannuoxin) |
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0} |
| Contraindicated (CN) |
| Oral |
| Rx in China |
| Clinical data |
|---|
| SIM0417, SSD8432 |
| Oral |
| SARS-CoV-2 3CLpro inhibitor |
| Not approved on its own |
| 72.5% |
| hepatic (CYP3A) |
| 3.1 h; 4.1 h with ritonavir |
| urine (55.4%), feces (36.7%) |
| IUPAC name |
| (8S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-7-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide |
| 168476146 |
| C22H30F3N5O4S2 |
| 549.63 g·mol−1 |
| Interactive image |
| SMILES |
| CC(C)(C)C@@HNC(=O)C(F)(F)F |
| InChI |
| InChI=InChI=1S/C22H30F3N5O4S2/c1-20(2,3)15(29-19(34)22(23,24)25)18(33)30-11-21(35-6-7-36-21)9-14(30)17(32)28-13(10-26)8-12-4-5-27-16(12)31/h12-15H,4-9,11H2,1-3H3,(H,27,31)(H,28,32)(H,29,34)/t12-,13-,14-,15+/m0/s1Key:LQBRGTAIBBFUJJ-ZQDZILKHSA-N |
Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, a CYP3A inhibitor.
It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. Results for the phase Ib trial are available. In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.
-
Nirmatrelvir/ritonavir
-
NHSA slideshow, also shows adverse effect data from phase II/III
Ask Mako anything about Simnotrelvir/ritonavir — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report